S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:ACET

Adicet Bio (ACET) Stock Forecast, Price & News

$1.43
+0.03 (+2.14%)
(As of 09/26/2023 ET)
Compare
Today's Range
$1.37
▼
$1.55
50-Day Range
$1.40
▼
$3.22
52-Week Range
$1.37
▼
$21.87
Volume
193,727 shs
Average Volume
634,223 shs
Market Capitalization
$61.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Adicet Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
1,123.8% Upside
$17.50 Price Target
Short Interest
Bearish
8.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1.84 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.93) to ($2.40) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

316th out of 964 stocks

Pharmaceutical Preparations Industry

129th out of 445 stocks

See Top Rated MarketRank™ Stocks Here

ACET stock logo

About Adicet Bio (NASDAQ:ACET) Stock

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.

ACET Price History

ACET Stock News Headlines

September 6, 2023 | msn.com
Truist Securities Reiterates Adicet Bio (ACET) Buy Recommendation
August 12, 2023 | finance.yahoo.com
Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 11, 2023 | msn.com
BTIG Maintains Adicet Bio (ACET) Buy Recommendation
August 9, 2023 | finance.yahoo.com
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue Estimates
August 9, 2023 | markets.businessinsider.com
Adicet Bio, Inc Q2 Loss increases, misses estimates
August 9, 2023 | finance.yahoo.com
Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 3, 2023 | finance.yahoo.com
Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
July 12, 2023 | benzinga.com
Adicet Bio Director Awarded $236K Worth of Stock Options
July 11, 2023 | finance.yahoo.com
Adicet Announces Appointment of Katie Peng to the Board of Directors
July 6, 2023 | msn.com
Adicet Bio (ACET) Price Target Decreased by 12.90% to 24.48
June 30, 2023 | benzinga.com
Massive Insider Trade At Adicet Bio
June 30, 2023 | benzinga.com
Director of Adicet Bio Purchased $1.83M In Stock
June 27, 2023 | msn.com
JMP downgrades Adicet to market perform, citing study delay
June 27, 2023 | msn.com
Adicet Bio Stock Craters 54% after JMP Downgrade
June 27, 2023 | markets.businessinsider.com
Analyst Downgrades Adicet Citing Uncertainty, Awaits Long-Term Data On Durability
June 27, 2023 | markets.businessinsider.com
6 Analysts Have This to Say About Adicet Bio
June 27, 2023 | msn.com
MoonLake Immunotherapeutics, Applied Digital And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
June 27, 2023 | markets.businessinsider.com
Adicet Bio (ACET) was downgraded to a Hold Rating at JMP Securities
June 27, 2023 | benzinga.com
Adicet Bio Stock Is Falling Premarket - Here's Why
June 13, 2023 | markets.businessinsider.com
JonesTrading Reaffirms Their Buy Rating on Adicet Bio (ACET)
June 2, 2023 | msn.com
JP Morgan Downgrades Adicet Bio (ACET)
June 1, 2023 | finance.yahoo.com
Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference
May 18, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Adicet Bio (ACET)
May 18, 2023 | msn.com
Adicet Bio's Cancer Candidate Shows Anti-Tumor Activity In Preclinical Study
May 18, 2023 | finance.yahoo.com
Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
See More Headlines
Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

ACET Company Calendar

Last Earnings
8/09/2023
Today
9/26/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Trading Companies & Distributors
Sector
Medical
Current Symbol
NASDAQ:ACET
CUSIP
00444610
CIK
2034
Web
www.aceto.com
Phone
(650) 503-9095
Fax
N/A
Employees
132
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.50
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+1,074.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-69,790,000.00
Net Margins
N/A
Pretax Margin
-279.27%
Return on Equity
-41.30%
Return on Assets
-36.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.08
Quick Ratio
11.08

Sales & Book Value

Annual Sales
$24.99 million
Price / Sales
2.57
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.82 per share
Price / Book
0.22

Miscellaneous

Outstanding Shares
43,070,000
Free Float
30,362,000
Market Cap
$64.17 million
Optionable
Optionable
Beta
1.96
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Chen Schor BAMr. Chen Schor BA (Age 51)
    CPA, CPA, M.B.A., MBA, CEO, Pres & Director
    Comp: $899.58k
  • Dr. Aya Jakobovits Ph.D. (Age 68)
    Founder & Independent Director
    Comp: $40k
  • Dr. Blake Aftab Ph.D. (Age 42)
    Sr. VP & Chief Scientific Officer
    Comp: $675.04k
  • Dr. Francesco Galimi M.D. (Age 55)
    Ph.D., Chief Medical Officer & Sr. VP
    Comp: $680.37k
  • Mr. Brian Nicholas Harvey (Age 62)
    Chief Financial Officer
  • Dr. Donald Healey Ph.D. (Age 61)
    Chief Technology Officer
  • Ms. Amy Locke
    Head of HR
  • Dr. Nancy L. Boman M.D.
    Ph.D., Sr. VP & Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ACET Stock - Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACET shares.
View ACET analyst ratings or view top-rated stocks.

What is Adicet Bio's stock price forecast for 2023?

7 brokerages have issued twelve-month target prices for Adicet Bio's shares. Their ACET share price forecasts range from $6.00 to $27.00. On average, they anticipate the company's share price to reach $17.50 in the next year. This suggests a possible upside of 1,074.5% from the stock's current price.
View analysts price targets for ACET or view top-rated stocks among Wall Street analysts.

How have ACET shares performed in 2023?

Adicet Bio's stock was trading at $8.94 on January 1st, 2023. Since then, ACET shares have decreased by 83.3% and is now trading at $1.49.
View the best growth stocks for 2023 here.

When is Adicet Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ACET earnings forecast.

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.07.

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

What is Adicet Bio's stock symbol?

Adicet Bio trades on the NASDAQ under the ticker symbol "ACET."

Who are Adicet Bio's major shareholders?

Adicet Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cowen AND Company LLC (6.60%), BlackRock Inc. (5.56%), Candriam S.C.A. (1.67%), Geode Capital Management LLC (1.47%), Decheng Capital Management III Cayman LLC (1.18%) and Dimensional Fund Advisors LP (0.77%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Carl L Gordon, Chen Schor, Don Healey, Francesco Galimi, Jay P Elliott and Steve Dubin.
View institutional ownership trends.

How do I buy shares of Adicet Bio?

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adicet Bio's stock price today?

One share of ACET stock can currently be purchased for approximately $1.49.

How much money does Adicet Bio make?

Adicet Bio (NASDAQ:ACET) has a market capitalization of $64.17 million and generates $24.99 million in revenue each year. The company earns $-69,790,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis.

How many employees does Adicet Bio have?

The company employs 132 workers across the globe.

How can I contact Adicet Bio?

Adicet Bio's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The official website for the company is www.aceto.com. The company can be reached via phone at (650) 503-9095 or via email at jburfening@lhai.com.

This page (NASDAQ:ACET) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -